scholarly journals Adoption of a Uniform Start Date for Internal Medicine Fellowships and Other Advanced Training: An AAIM White Paper

2015 ◽  
Vol 128 (9) ◽  
pp. 1039-1043 ◽  
Author(s):  
J. Christian Barrett ◽  
Richard Alweis ◽  
Michael Frank ◽  
Alec O'Connor ◽  
John F. McConville ◽  
...  
2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Sevil Aliyeva ◽  
Kunal Kirloskar ◽  
Kedaari Anant ◽  
Pamela Schroeder

Abstract It is well known that Lithium causes various types of thyroid dysfunction. Thus, multiple professional guidelines, for example the American Psychiatry Association, recommend that thyroid function be assessed before starting lithium therapy, within the first 6 months of initiation, and then every 6 to 12 months. We hypothesized that these recommendations are not consistently followed by all types of providers. Methods A total of 796 patients were identified by chart review with age ≥18 years and ICD 9/10 codes for bipolar disorder or on lithium in outpatient clinics in our multicenter system from January 2013 to December 2017. Results Lithium start date was known in 472 (59.3%) of 796 patients. Of these 796 patients, 518 (65 %) were followed by psychiatry, 25 (3%) by family medicine, 60 (7.5%) by internal medicine, and 193 (24%) by other specialties including endocrinology and emergency department. Patients with unknown start date were excluded from analysis of baseline and follow-up TSH. Baseline TSH was done in 178 (37%) of patients with known start date. Of these patients, 141 (79%) were followed by psychiatry, 13 (7%) by internal medicine, and 8 (4%) by family medicine. Of the 472 patients, 76 (16%) had 6-month TSH by psychiatry (42; 60.5%), internal medicine (17; 22%), and family medicine (3; 4%). Of the 796 patients on lithium, 568 (71%) had random TSH values, 200 (25%) had abnormal thyroid function tests (TFTs), and only 69 (34%) had baseline TFTs before lithium was started. Of the 200 patients with abnormal TFTs, 90 (45%) developed thyroid disease. The odds of baseline TSH for family practice and internal medicine were not significantly different than for psychiatry, (OR = 1.3 p = 0.6, and OR = 0.7, p = 0.3, respectively). Internal medicine had 5.1 times higher odds of TSH at 6 months compared with psychiatry (p <0.001). The odds of 6-month TSH for family practice were not significantly different than for psychiatry. Conclusion Our findings revealed that TSH was not checked in most patients before starting lithium therapy and TSH values were not followed at recommended intervals. This raises the concern that a large number of patients may have undiagnosed thyroid dysfunction due to inappropriate follow up. Future plans include a quality improvement project to focus on improving practice patterns, such as EMR reminders to prompt providers when TFTs are due and educating providers about the guidelines.


2014 ◽  
Vol 19 (5) ◽  
pp. 13-15
Author(s):  
Stephen L. Demeter

Abstract A long-standing criticism of the AMA Guides to the Evaluation of Permanent Impairment (AMA Guides) has been the inequity between the internal medicine ratings and the orthopedic ratings; in the comparison, internal medicine ratings appear inflated. A specific goal of the AMA Guides, Sixth Edition, was to diminish, where possible, those disparities. This led to the use of the International Classification of Functioning, Disability, and Health from the World Health Organization in the AMA Guides, Sixth Edition, including the addition of the burden of treatment compliance (BOTC). The BOTC originally was intended to allow rating internal medicine conditions using the types and numbers of medications as a surrogate measure of the severity of a condition when other, more traditional methods, did not exist or were insufficient. Internal medicine relies on step-wise escalation of treatment, and BOTC usefully provides an estimate of impairment based on the need to be compliant with treatment. Simplistically, the need to take more medications may indicate a greater impairment burden. BOTC is introduced in the first chapter of the AMA Guides, Sixth Edition, which clarifies that “BOTC refers to the impairment that results from adhering to a complex regimen of medications, testing, and/or procedures to achieve an objective, measurable, clinical improvement that would not occur, or potentially could be reversed, in the absence of compliance.


Sign in / Sign up

Export Citation Format

Share Document